The change over time of vital signs with consideration for opioid use in the last 2 weeks of life among cancer patients in a palliative care unit: Continuous measurement of vital signs using a non-wearable monitor.
non-wearable monitor
palliative care
terminal cancer patients
vital signs
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
08
10
2021
received:
26
07
2021
accepted:
09
10
2021
pubmed:
1
12
2021
medline:
18
3
2022
entrez:
30
11
2021
Statut:
ppublish
Résumé
The aim of this study was to examine the following by using a non-wearable monitor: (ⅰ) the trajectory of vital signs (VS) in the last 2 weeks of life among cancer patients, and (ⅱ) the difference in change over time of VS between cancer patients with and without opioid use. We conducted a longitudinal study involving cancer patients in a palliative care unit (PCU) from April 2018 to October 2019. VS were collected continuously using a non-wearable monitor, and we calculated the means of respiratory rate (RR) and heart rate (HR) per hour, and counts of apnea per hour as outcome variables. Explanatory variables were time (subtracting time of death from measurement time of VS, divided by 36) and opioid use. Mean difference (MD) of time represented the slope per hour of VS values. First, we analyzed the associations between VS per hour and time using a linear mixed model (LMM) with random intercepts and slope over time. Second, we analyzed the associations between VS and interaction term between time and opioid use. We analyzed 26 cancer patients. RR (MD: 0.27 beats/min [95% CI: 0.27-0.28]), HR (MD: 1.51 beats/min [95% CI: 1.50-1.52]), and apnea (MD: 0.71 count/hour [95% CI: 0.70-0.72]) significantly increased hourly. In addition, RR was significantly associated with interaction term (MD: -1.59 beats/min [95% CI: -3.11 to -0.07]), which indicates that there is a difference in the slope of RR between opioid users and non-users. We have successfully described the trajectory of VS in high-resolution under conditions of a natural end of life in PCU.
Identifiants
pubmed: 34845870
doi: 10.1002/cam4.4382
pmc: PMC8683542
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8799-8807Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Med. 2021 Dec;10(24):8799-8807
pubmed: 34845870
Stat Med. 2013 Jul 10;32(15):2585-94
pubmed: 23242852
J Formos Med Assoc. 2009 Mar;108(3):231-9
pubmed: 19293039
Support Care Cancer. 2019 Jun;27(6):1973-1984
pubmed: 30863893
J Palliat Med. 2021 Nov;24(11):1634-1640
pubmed: 33733880
J Pain Symptom Manage. 2015 Apr;49(4):690-6
pubmed: 25261639
J Pain Symptom Manage. 1990 Apr;5(2):83-93
pubmed: 2348092
PLoS One. 2019 Jan 15;14(1):e0210875
pubmed: 30645637
Future Oncol. 2017 Apr;13(9):833-841
pubmed: 27875910
J Pain Symptom Manage. 2014 Oct;48(4):510-7
pubmed: 24731412
Drug Discov Ther. 2017;11(3):126-132
pubmed: 28757513
Support Care Cancer. 1999 May;7(3):128-33
pubmed: 10335930
J Physiol Anthropol. 2011;30(3):103-9
pubmed: 21636953